Bharat Parenterals is planning to acquire additional 99,85,477 equity shares having Face value Rs 10 per share with a premium of Rs 54.90 per share aggregating of Rs 64.90 per share of Innoxel Lifesciences, a Subsidiary company of the company on a preferential basis. The Investment is made for expansion of existing plant and working capital requirement of the Subsidiary Company. The said acquisition is expected to be completed by June 30, 2024 subject to approval of shareholders.
Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: